UK markets closed
  • FTSE 100

    7,053.98
    -24.37 (-0.34%)
     
  • FTSE 250

    23,618.37
    -211.81 (-0.89%)
     
  • AIM

    1,268.19
    -4.21 (-0.33%)
     
  • GBP/EUR

    1.1674
    -0.0009 (-0.08%)
     
  • GBP/USD

    1.3671
    -0.0049 (-0.36%)
     
  • BTC-GBP

    30,513.79
    -1,730.86 (-5.37%)
     
  • CMC Crypto 200

    1,040.34
    -62.72 (-5.69%)
     
  • S&P 500

    4,442.93
    -6.05 (-0.14%)
     
  • DOW

    34,721.38
    -43.44 (-0.12%)
     
  • CRUDE OIL

    73.61
    +0.31 (+0.42%)
     
  • GOLD FUTURES

    1,751.80
    +2.00 (+0.11%)
     
  • NIKKEI 225

    30,248.81
    +609.41 (+2.06%)
     
  • HANG SENG

    24,192.16
    -318.82 (-1.30%)
     
  • DAX

    15,527.43
    -116.54 (-0.74%)
     
  • CAC 40

    6,634.20
    -67.78 (-1.01%)
     

Why Iovance Biotherapeutics Soared 40% In June

·2-min read
Why Iovance Biotherapeutics Soared 40% In June
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The biopharma outfit has put some red flags in the rearview mirror, and sees a plausible approval on the horizon.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting